Insider Selling: DaVita HealthCare Partners Director Sells 42,519 Shares of Stock (DVA)
DaVita HealthCare Partners (NYSE:DVA) Director William L. Roper unloaded 42,519 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $66.37, for a total value of $2,821,986.03. Following the completion of the transaction, the director now directly owns 4,994 shares in the company, valued at approximately $331,452. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
DaVita HealthCare Partners (NYSE:DVA) opened at 66.07 on Thursday. DaVita HealthCare Partners has a 52-week low of $52.75 and a 52-week high of $68.84. The stock has a 50-day moving average of $64.80 and a 200-day moving average of $59.49. The company has a market cap of $14.084 billion and a price-to-earnings ratio of 22.64.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $0.99 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.91 by $0.92. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $2.92 billion. During the same quarter last year, the company posted $1.68 earnings per share. DaVita HealthCare Partners’s revenue was up 23.6% compared to the same quarter last year. Analysts expect that DaVita HealthCare Partners will post $3.73 EPS for the current fiscal year.
A number of analysts have recently weighed in on DVA shares. Analysts at Deutsche Bank raised their price target on shares of DaVita HealthCare Partners from $72.00 to $74.00 in a research note on Thursday, February 13th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of DaVita HealthCare Partners from $70.00 to $75.00 in a research note on Thursday, February 13th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Wednesday, February 12th. They now have a $68.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $94.56.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.